{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T21:51:34Z","timestamp":1769637094282,"version":"3.49.0"},"reference-count":20,"publisher":"American Academy of Pediatrics (AAP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,12,1]]},"abstract":"<jats:p>Objective. Symptomatic patent ductus arteriosus (sPDA) is a common problem in premature infants and can be treated effectively with intravenous indomethacin, leading to permanent ductal closure in 70% to 80% of infants. Infants who do not respond to pharmacologic closure of the duct ultimately have to undergo surgical or interventional closure of the PDA. Optimizing the pharmacologic treatment could offer an interesting approach to reduce the number of infants who need surgical closure of the duct.<\/jats:p>\n               <jats:p>Methods. We conducted a retrospective analysis in infants who were &amp;lt;33 weeks\u2019 gestation, had sPDA, and were treated with high-dose intravenous indomethacin. From 1993 to 2002, 129 infants with sPDA received indomethacin after diagnosis of sPDA was confirmed by echocardiography. Treatment was started in all infants with intravenous indomethacin (0.2 mg\/kg given 5 times at 0 hours, 12 hours, 24 hours, 48 hours, and 72 hours). When the ductus was still open at 36 hours, indomethacin every 12 hours was continued and single doses increased up to 1 mg\/kg until ductal closure was achieved.<\/jats:p>\n               <jats:p>Results. In 68 (53%) of 129 infants who were treated with indomethacin, ductal closure occurred during intermediate-dose indomethacin therapy (up to 1.5 mg\/kg total dose). In the 61 initial nonresponders, the continuation of indomethacin led to ductal closure in 59 infants. When infants who were treated with an intermediate dose were compared with the initial nonresponders, no differences in the incidences of renal or electrolyte abnormalities, gastrointestinal bleeding, intraventricular hemorrhage, or periventricular leukomalacia were found.<\/jats:p>\n               <jats:p>Conclusions. High-dose indomethacin after intermediate-dose therapy resulted in an overall closure rate of 98.5% (127 of 129). Although single indomethacin doses of up to 1 mg\/kg were given, high-dose indomethacin was safe.<\/jats:p>","DOI":"10.1542\/peds.2005-0293","type":"journal-article","created":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T20:44:17Z","timestamp":1133469857000},"page":"1361-1366","source":"Crossref","is-referenced-by-count":53,"title":["Effectiveness and Side Effects of an Escalating, Stepwise Approach to Indomethacin Treatment for Symptomatic Patent Ductus Arteriosus in Premature Infants Below 33 Weeks of Gestation"],"prefix":"10.1542","volume":"116","author":[{"given":"Markus","family":"Sperandio","sequence":"first","affiliation":[{"name":"Division of Neonatology, Department of Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernd","family":"Beedgen","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Department of Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Feneberg","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Department of Pediatrics"},{"name":"Coordination Center for Clinical Trials, University of Heidelberg, Heidelberg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christina","family":"Huppertz","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Department of Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ju\u0308rgen","family":"Bru\u0308ssau","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Department of Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Po\u0308schl","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Department of Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otwin","family":"Linderkamp","sequence":"additional","affiliation":[{"name":"Division of Neonatology, Department of Pediatrics"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"417","published-online":{"date-parts":[[2005,12,1]]},"reference":[{"key":"2021121003225942200_R1","doi-asserted-by":"crossref","unstructured":"Friedman WF, Hirschklau MJ, Printz MP, Pitlick PT, Kirkpatrick SE. Pharmacologic closure of patent ductus arteriosus in the premature infant. N Engl J Med.\u20081976;295:526\u2013529","DOI":"10.1056\/NEJM197609022951003"},{"key":"2021121003225942200_R2","doi-asserted-by":"crossref","unstructured":"Heymann MA, Rudolph AM, Silverman NH. Closure of the ductus arteriosus in premature infants by inhibition of prostaglandin synthesis. N Engl J Med.\u20081976;295:530\u2013533","DOI":"10.1056\/NEJM197609022951004"},{"key":"2021121003225942200_R3","doi-asserted-by":"crossref","unstructured":"Hammerman C. Patent ductus arteriosus. Clinical relevance of prostaglandins and prostaglandin inhibitors in PDA pathophysiology and treatment. Clin Perinatol.\u20081995;22:457\u2013479","DOI":"10.1016\/S0095-5108(18)30293-8"},{"key":"2021121003225942200_R4","doi-asserted-by":"crossref","unstructured":"Itabashi K, Ohno T, Nishida H. Indomethacin responsiveness of patent ductus arteriosus and renal abnormalities in preterm infants treated with indomethacin. J Pediatr.\u20082003;143:203\u2013207","DOI":"10.1067\/S0022-3476(03)00303-2"},{"key":"2021121003225942200_R5","unstructured":"Herrera C, Holberton J, Davis P. Prolonged versus short course of indomethacin for the treatment of patent ductus arteriosus in preterm infants. Cochrane Database Syst Rev.\u20082004;(1):CD003480"},{"key":"2021121003225942200_R6","doi-asserted-by":"crossref","unstructured":"Rhodes PG, Ferguson MG, Reddy NS, Joransen JA, Gibson J. Effects of prolonged versus acute indomethacin therapy in very low birth-weight infants with patent ductus arteriosus. Eur J Pediatr.\u20081988;147:481\u2013484","DOI":"10.1007\/BF00441971"},{"key":"2021121003225942200_R7","doi-asserted-by":"crossref","unstructured":"Rennie JM, Cooke RW. Prolonged low dose indomethacin for persistent ductus arteriosus of prematurity. Arch Dis Child.\u20081991;66(Spec No):55\u201358","DOI":"10.1136\/adc.66.1_Spec_No.55"},{"key":"2021121003225942200_R8","doi-asserted-by":"crossref","unstructured":"Tammela O, Ojala R, Iivainen T, et al. Short versus prolonged indomethacin therapy for patent ductus arteriosus in preterm infants. J Pediatr.\u20081999;134:552\u2013557","DOI":"10.1016\/S0022-3476(99)70239-8"},{"key":"2021121003225942200_R9","doi-asserted-by":"crossref","unstructured":"Lee J, Rajadurai VS, Tan KW, Wong KY, Wong EH, Leong JY. Randomized trial of prolonged low-dose versus conventional-dose indomethacin for treating patent ductus arteriosus in very low birth weight infants. Pediatrics.\u20082003;112:345\u2013350","DOI":"10.1542\/peds.112.2.345"},{"key":"2021121003225942200_R10","doi-asserted-by":"crossref","unstructured":"Seyberth HW, Knapp G, Wolf D, Ulmer HE. Introduction of plasma indomethacin level monitoring and evaluation of an effective threshold level in very low birth weight infants with symptomatic patent ductus arteriosus. Eur J Pediatr.\u20081983;141:71\u201376","DOI":"10.1007\/BF00496793"},{"key":"2021121003225942200_R11","doi-asserted-by":"crossref","unstructured":"Schuster V, von Stockhausen HB, Seyberth HW. Effects of highly overdosed indomethacin in a preterm infant with symptomatic patent ductus arteriosus. Eur J Pediatr.\u20081990;149:651\u2013653","DOI":"10.1007\/BF02034756"},{"key":"2021121003225942200_R12","doi-asserted-by":"crossref","unstructured":"Narayanan M, Schlueter M, Clyman RI. Incidence and outcome of a 10-fold indomethacin overdose in premature infants. J Pediatr.\u20081999;135:105\u2013107","DOI":"10.1016\/S0022-3476(99)70337-9"},{"key":"2021121003225942200_R13","doi-asserted-by":"crossref","unstructured":"Bellander M, Ley D, Polberger S, Hellstrom-Westas L. Tolerance to early human milk feeding is not compromised by indomethacin in preterm infants with persistent ductus arteriosus. Acta Paediatr.\u20082003;92:1074\u20131078","DOI":"10.1111\/j.1651-2227.2003.tb02580.x"},{"key":"2021121003225942200_R14","doi-asserted-by":"crossref","unstructured":"Papile L-A, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1500g. J Pediatr.\u20081978;92:529\u2013534","DOI":"10.1016\/S0022-3476(78)80282-0"},{"key":"2021121003225942200_R15","doi-asserted-by":"crossref","unstructured":"Walsh M, Kliegman R. NEC: treatment based on staging criteria. Pediatr Clin North Am.\u20081986;33:179\u2013199","DOI":"10.1016\/S0031-3955(16)34975-6"},{"key":"2021121003225942200_R16","doi-asserted-by":"crossref","unstructured":"Fujii AM, Brown E, Mirochnick M, O\u2019Brien S, Kaufman G. Neonatal necrotizing enterocolitis with intestinal perforation in extremely premature infants receiving early indomethacin treatment for patent ductus arteriosus. J Perinatol.\u20082002;22:535\u2013540","DOI":"10.1038\/sj.jp.7210795"},{"key":"2021121003225942200_R17","unstructured":"Jackson JK, Abdel-Rahman SM, Reavey D, Leeks S, Garg U, Hall RT. Use of indomethacin serum concentration in predicting effectiveness of dosing for symptomatic patent ductus arteriosus [abstract]. Hot Topics in Neonatology. Washington DC; 2000:352"},{"key":"2021121003225942200_R18","doi-asserted-by":"crossref","unstructured":"Van Overmeire B, Smets K, Lecoutere D, et al. A comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med.\u20082000;343:674\u2013681","DOI":"10.1056\/NEJM200009073431001"},{"key":"2021121003225942200_R19","doi-asserted-by":"crossref","unstructured":"Ahlfors CE. Effect of ibuprofen on bilirubin-albumin binding. J Pediatr.\u20082004;144:386\u2013388","DOI":"10.1016\/j.jpeds.2003.11.027"},{"key":"2021121003225942200_R20","doi-asserted-by":"crossref","unstructured":"Gournay V, Savagner C, Thiriez G, Kuster A, Roze JC. Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants. Lancet.\u20082002;359:1486\u20131488","DOI":"10.1016\/S0140-6736(02)08424-6"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/116\/6\/1361\/1067501\/zpe01205001361.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/116\/6\/1361\/1067501\/zpe01205001361.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T10:01:28Z","timestamp":1639130488000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/116\/6\/1361\/63008\/Effectiveness-and-Side-Effects-of-an-Escalating"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12,1]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2005,12,1]]},"published-print":{"date-parts":[[2005,12,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2005-0293","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12,1]]}}}